Heliyon (Sep 2023)

Tobramycin-loaded nanoparticles of thiolated chitosan for ocular drug delivery: Preparation, mucoadhesion and pharmacokinetic evaluation

  • Sadaf Javed,
  • Ghulam Abbas,
  • Shahid Shah,
  • Akhtar Rasul,
  • Muhammad Irfan,
  • Ammara Saleem,
  • Khaled M. Hosny,
  • Sahar M. Bukhary,
  • Awaji Y. Safhi,
  • Fahad Y. Sabei,
  • Mohammed A. Majrashi,
  • Hala M. Alkhalidi,
  • Mohammed Alissa,
  • Sajid Mehmood Khan,
  • Muhammad Hanif

Journal volume & issue
Vol. 9, no. 9
p. e19877

Abstract

Read online

The present work aimed to develop nanoparticles of tobramycin (TRM) using thiolated chitosan (TCS) in order to improve the mucoadhesion, antibacterial effect and pharmacokinetics. The nanoparticles were evaluated for their compatibility, thermal stability, particle size, zeta potential, mucoadhesion, drug release, kinetics of TRM release, corneal permeation, toxicity and ocular irritation. The thiolation of chitosan was confirmed by 1H NMR and FTIR, which showed peaks at 6.6 ppm and 1230 cm−1, respectively. The nanoparticles had a diameter of 73 nm, a negative zeta potential (−21 mV) and a polydispersity index of 0.15. The optimized formulation, NT8, exhibited the highest values of mucoadhesion (7.8 ± 0.541h), drug loading (87.45 ± 1.309%), entrapment efficiency (92.34 ± 2.671%), TRM release (>90%) and corneal permeation (85.56%). The release pattern of TRM from the developed formulations was fickian diffusion. TRM-loaded nanoparticles showed good antibacterial activity against Pseudomonas aeruginosa. The optimized formulation NT8 (0.1% TRM) greatly increased the AUC(0-∞) (1.5-fold) while significantly reducing the clearance (5-fold) compared to 0.3% TRM. Pharmacokinetic parameters indicated improved ocular retention and bioavailability of TRM loaded nanoparticles. Our study demonstrated that the TRM-loaded nanoparticles had improved mucoadhesion and pharmacokinetics and a suitable candidate for effective treatment of ocular bacterial infections.

Keywords